EMERGENCY:Sudden numbness in one arm or one side of the face in a diabetic patient may be a stroke, not neuropathy. —call040-46324365immediately — 24 hours, 7 days— 24/7
Diabetic Neuropathy Treatment in Hyderabad — KIMS Neuroscience
India has approximately 101 million people living with diabetes — the second-largest diabetic population in the world. Of these, approximately 50% will develop diabetic peripheral neuropathy (DPN) within 10 years of diagnosis, and the risk reaches 70–80% after 25 years. Diabetic neuropathy is the single most common cause of peripheral neuropathy seen at KIMS Hyderabad, and it is also one of the most important — because it causes chronic pain, foot ulcers, amputations, and autonomic dysfunction that significantly reduces quality of life and life expectancy.
About This Condition
Diabetic Neuropathy at a Glance
The essential facts that shape how diabetic neuropathy is recognised and treated at KIMS — the 50% lifetime prevalence among Indian diabetics, the vasa-nervorum ischaemic mechanism, the length-dependent stocking-glove pattern across sensory, motor and autonomic fibres, the painful and autonomic variants, the NCS/EMG gold standard, HbA1c optimisation as the most powerful treatment, the pregabalin/duloxetine/gabapentin pain ladder, and daily foot care to prevent Charcot foot.
Prevalence in India
50% of diabetics develop neuropathy · Most common peripheral neuropathy in India.
Mechanism
Chronic hyperglycaemia damages small blood vessels (vasa nervorum), causing ischaemic nerve injury.
Fibre types affected
Sensory + motor + autonomic (all three).
Pattern
Length-dependent axonal: feet and toes first, moves upward symmetrically.
Painful variant
Burning, electric, allodynia in feet — affects 25–30% of DPN patients.
Autonomic variant
Postural hypotension, gastroparesis, erectile dysfunction, bladder dysfunction.
Gold standard test
NCS/EMG: used when the diagnosis is atypical or uncertain, or to exclude alternative causes; not required to confirm a typical clinical DPN presentation.
Primary treatment
HbA1c optimisation (target <7%) — slows and may partially reverse early DPN.
Pain medications
Pregabalin 150–300 mg/day · Duloxetine 60–90 mg/day · Gabapentin 900–1800 mg/day.
Foot care
Daily foot inspection · Protective footwear · Podiatry · Prevent Charcot foot.
Diabetic Neuropathy — India's Most Common Peripheral Neuropathy
India has approximately 101 million people living with diabetes — the second-largest diabetic population in the world. Of these, approximately 50% will develop diabetic peripheral neuropathy (DPN) within 10 years of diagnosis, and the risk reaches 70–80% after 25 years. Diabetic neuropathy is the single most common cause of peripheral neuropathy seen at KIMS Hyderabad, and it is also one of the most important — because it causes chronic pain, foot ulcers, amputations, and autonomic dysfunction that significantly reduces quality of life and life expectancy.
The good news is that diabetic neuropathy is preventable, stabilisable, and — when caught early — partially reversible. The primary treatment is not a drug. It is blood sugar control. Every reduction in HbA1c slows the progression of nerve damage. The secondary treatment is pain management and foot protection. At KIMS, the neuropathy team works with the endocrinology team to integrate diabetes management and neuropathy treatment into a single coordinated care plan.
Book a Consultation
Speak directly with the KIMS diabetic neuropathy team — neurology, clinical neurophysiology (NCS/EMG and autonomic function testing), endocrinology, neuropathology (skin punch biopsy for small-fibre quantification), podiatry and orthotics, and orthopaedic surgery for Charcot foot — all coordinated under one roof. No referral required. Monday to Saturday.
040-44885000Stroke emergency line: 040-46324365Who Gets Diabetic Neuropathy and Why
Two foundational pillars that explain why diabetic neuropathy presents the way it does — the vasa-nervorum ischaemia from chronic hyperglycaemia that drives the length-dependent stocking-glove dying-back pattern, and the key risk factors (diabetes duration, glycaemic control, hypertension, dyslipidaemia, smoking, obesity, alcohol) including Indian-specific co-existing vitamin B12 deficiency and hypothyroidism.
How chronic hyperglycaemia damages the peripheral nerves
Diabetic neuropathy is caused by the damaging effect of chronic high blood glucose on the small blood vessels that supply peripheral nerves (called vasa nervorum — vessels of the nerves). When these tiny vessels are damaged, nerves receive less oxygen and fewer nutrients. Over months to years, nerve fibres begin to die from the distal (far) end inward. Since the longest nerves in the body run to the toes, the toes are always affected first. As nerve fibres continue to die, the level of numbness gradually climbs up the legs — the "stocking" pattern. When it reaches the knees, the fingertips begin to be affected — the "glove" pattern.
Key risk factors and Indian-specific co-existing deficiencies
Key risk factors for developing DPN include: duration of diabetes (the longer the diabetes, the higher the risk); poor glycaemic control (HbA1c above 8–9%); hypertension; dyslipidaemia (high triglycerides, low HDL); smoking; obesity; and alcohol use. In Indian patients, co-existing vitamin B12 deficiency (from vegetarian diet or metformin use) and hypothyroidism frequently worsen neuropathy or are confused with DPN. At KIMS, every DPN evaluation includes serum B12, folate, and TSH, not just HbA1c.
Metformin and Vitamin B12 depletion — an important India-specific consideration
Metformin, the most widely prescribed diabetes medication in India, reduces the absorption of vitamin B12 from the gut. Long-term metformin use (especially at higher doses) depletes serum B12 over years. This creates a situation where a patient with diabetes is developing DPN from hyperglycaemia and also developing B12-deficiency neuropathy from their diabetes medication — both at the same time. The two conditions are clinically similar but require different treatments. At KIMS, serum B12, methylmalonic acid (MMA), and homocysteine are measured in all diabetic patients on metformin presenting with neuropathy.
Clinical Features
The five pillars of clinical recognition at KIMS — the burning feet that disrupt sleep (the most common presenting complaint), the painless numbness that precedes diabetic foot ulceration and amputation, the allodynia that signals small-fibre involvement, the autonomic neuropathy that drives cardiovascular and gastrointestinal complications, and the limb-threatening Charcot neuroarthropathy.
Burning feet — the most common presenting complaint
The most common presenting symptom of DPN in Indian patients is burning pain in the feet, worse at night. The pain is typically described as "soles on fire," "electric shocks," or "pins and needles that never stop." It is worst at night and can severely disrupt sleep. This symptom is caused by abnormal spontaneous firing of damaged small-diameter sensory nerve fibres (C fibres and A-delta fibres). About 25–30% of DPN patients have this painful variant — the rest have painless numbness that they may not notice until a foot ulcer develops.
Numbness and reduced protective sensation
Painless DPN is more dangerous than painful DPN, because the patient cannot feel injury to the foot. Patients may step on a nail, develop a blister from tight footwear, or sustain a burn from a hot water bottle — without feeling pain. The foot then develops an ulcer, which can become infected and, if untreated, lead to gangrene and amputation. In India, diabetic foot disease is the most common reason for non-traumatic lower limb amputation. At KIMS, every DPN patient receives foot care education and is referred for podiatric assessment.
Allodynia — when a bedsheet causes pain
Allodynia means that a normally painless stimulus — such as the light touch of a bedsheet or clothing on the skin — produces pain. This occurs in painful DPN because the damaged sensory nerve fibres become hypersensitised and fire in response to stimuli that should not cause pain. Allodynia is a reliable clinical indicator of small fibre involvement and is a specific feature of neuropathic (nerve) pain as opposed to musculoskeletal or joint pain.
Autonomic neuropathy — the invisible complication
Autonomic neuropathy affects the nerves that control involuntary body functions. In diabetic autonomic neuropathy: the heart rate does not vary normally with breathing (reduced heart rate variability, HRV — an independent predictor of sudden cardiac death); blood pressure drops when standing up (orthostatic hypotension — causing dizziness, falls, and fainting); the stomach empties too slowly (gastroparesis — causing bloating, nausea, and erratic blood glucose levels after meals); bladder does not empty fully (neurogenic bladder — causing overflow incontinence and urinary tract infections); and sexual function is impaired in men (erectile dysfunction) and women (reduced lubrication and arousal). Autonomic neuropathy affects approximately 20–25% of patients with Type 2 diabetes in India.
Charcot neuroarthropathy — the destructive foot complication
Charcot neuroarthropathy (Charcot foot) is a severe complication of DPN where the bones of the foot collapse and deform because the protective pain sensation that normally prevents overloading of the joints is absent. The foot becomes hot, red, and swollen — mistaken for infection or gout. X-ray shows bony destruction, joint dislocation, and collapse of the arch. Charcot foot requires immediate offloading in a total contact cast and specialist orthopaedic or podiatric review. It is a limb-threatening emergency. At KIMS, urgent assessment for Charcot foot is available: call 040-44885000.
Diagnosis at KIMS
Diagnosis at KIMS
Diabetic neuropathy is diagnosed at KIMS with a structured workflow that combines NCS/EMG, glycaemic profiling (HbA1c, fasting/post-prandial glucose, lipid profile), B12/MMA/homocysteine screening (essential in metformin-treated Indian patients), autonomic function testing, and — when NCS is normal but suspicion is high — skin punch biopsy for intraepidermal nerve fibre density :
Nerve Conduction Study (NCS) — for atypical, uncertain, or diagnostically complex presentations
NCS in DPN shows a characteristic pattern: reduced sensory nerve action potential (SNAP) amplitudes in the sural nerve and superficial peroneal nerve (the longest sensory nerves in the leg), with relatively mildly slowed conduction velocities (axonal pattern, not demyelinating). Motor NCS of the common peroneal nerve shows reduced compound muscle action potential (CMAP) amplitude. In early DPN, NCS may be normal and skin punch biopsy for intraepidermal nerve fibre (IENF) density is a more sensitive early test (available at KIMS). As DPN progresses, NCS abnormalities become more prominent and bilateral.
HbA1c and fasting glucose — current glycaemic status
HbA1c measures average blood glucose over the preceding 3 months. Every 1% reduction in HbA1c (e.g., from 9% to 8%) reduces the risk of neuropathy progression by approximately 30%. This is the most powerful treatment for DPN. Fasting and post-prandial glucose, glucose variability (continuous glucose monitoring where available), and lipid profile are also assessed.
Serum B12, methylmalonic acid, and homocysteine
Serum B12 below 200 pg/mL is deficient; 200–300 pg/mL is borderline. Methylmalonic acid (MMA) and homocysteine are more sensitive functional markers of B12 status — they rise before serum B12 falls below the normal range. In patients on metformin, B12 should be checked annually. When B12 deficiency coexists with DPN, both must be treated simultaneously.
Autonomic function testing
At KIMS, autonomic function testing includes: heart rate variability with deep breathing (Ewing test); Valsalva manoeuvre ratio; lying-to-standing blood pressure change (orthostatic hypotension). These non-invasive tests quantify cardiovascular autonomic neuropathy and estimate cardiac autonomic risk.
Skin punch biopsy for small fibre neuropathy
When the clinical suspicion of DPN is high but NCS is normal (which occurs in early DPN affecting predominantly the small C and A-delta fibres, which are not measured by standard NCS), skin punch biopsy at the distal leg measures the density of intraepidermal nerve fibres. Reduced IENF density below the age-adjusted normative value confirms small fibre neuropathy (SFN) — the earliest form of DPN.
Treatment
Treatment at KIMS
The KIMS diabetic neuropathy programme is built around four integrated treatment areas — blood glucose optimisation as the most effective single intervention (with endocrinology coordination), neuropathic pain management (pregabalin, duloxetine, gabapentin, TCAs, topical capsaicin/lidocaine), foot care and complication prevention (podiatry, orthotics, Charcot foot surveillance), and targeted management of autonomic neuropathy (orthostatic hypotension, gastroparesis, erectile dysfunction).
Glucose Optimisation, Pain Management, Foot Care, and Autonomic Neuropathy
Primary Treatment: Blood Glucose Optimisation: The most effective treatment for diabetic neuropathy is not a drug — it is controlling blood glucose. The DCCT trial (Type 1 diabetes) showed that intensive glycaemic control reduces the risk of DPN by 60%. The UKPDS trial showed similar benefit in Type 2 diabetes. At KIMS, the neuropathy team works in parallel with endocrinology to set individualised HbA1c targets, review and adjust diabetes medications, and address contributing metabolic factors (blood pressure control, statin for dyslipidaemia, smoking cessation).
Neuropathic Pain Management — Pregabalin (150–300 mg/day): Alpha-2-delta ligand; reduces abnormal nerve firing. First-line for painful DPN. Start 75 mg twice daily; titrate to 150 mg twice daily over 1–2 weeks. Side effects: dizziness and weight gain (relevant in Indian diabetics — increases insulin resistance). Available in India as brand Lyrica and generics.
Duloxetine (60–90 mg/day): Serotonin-noradrenaline reuptake inhibitor (SNRI); reduces central pain amplification. Equally effective as pregabalin for painful DPN and has the advantage of being weight-neutral. Start 30 mg/day for 1 week then 60 mg/day. Avoid in hepatic dysfunction.
Gabapentin (900–1800 mg/day): Similar mechanism to pregabalin. Often used as the first-line agent due to lower cost in India. Three-times-daily dosing is less convenient than twice-daily pregabalin. Titrate slowly to reduce sedation.
Tricyclic antidepressants (amitriptyline 10–25 mg at night): Effective for neuropathic pain at low doses (below the antidepressant dose). Useful where cost is a concern. Caution in autonomic neuropathy (worsens orthostatic hypotension and urinary retention) and cardiac conduction disease (QTc prolongation).
Topical capsaicin or lidocaine patches: Useful for localised painful areas when systemic medications are not tolerated. Capsaicin depletes substance P from C fibres. Available on prescription.
Foot Care and Complication Prevention: Daily foot inspection (using a mirror for the sole), washing with lukewarm water, gentle moisturising (except between toes), protective footwear with adequate depth and cushioning, and avoidance of barefoot walking are essential. At KIMS, diabetic patients with neuropathy are referred for podiatric assessment and custom orthotic prescription. Patients with Charcot foot receive urgent orthopaedic or podiatric review.
Autonomic Neuropathy Management — Orthostatic hypotension: Increase salt and fluid intake, compression stockings, fludrocortisone or midodrine in refractory cases, and head-of-bed elevation at 30° to reduce nocturnal natriuresis.
Gastroparesis: Small, frequent meals; low-fat and low-fibre diet; metoclopramide (short-term, with caution) or domperidone. Erythromycin as prokinetic. Continuous glucose monitoring to anticipate postprandial glucose variability.
Erectile dysfunction: PDE-5 inhibitors (sildenafil, tadalafil) effective in diabetic autonomic neuropathy. Discuss cardiovascular risk before prescribing.
Related Conditions
Diabetic neuropathy belongs to the family of peripheral neuropathies evaluated and managed at KIMS Neuroscience. Explore related neuropathic conditions or return to the peripheral neuropathies hub.
FAQs
Frequently Asked Questions
Burning feet at night, numbness that has moved from your toes to your ankles, dizziness when you stand up — if you have diabetes, these are signs that your nerves need attention now.
At KIMS Hyderabad, the neuropathy evaluation takes a single appointment: NCS, blood panel, foot exam, and a treatment plan. The most important intervention — optimising your HbA1c — starts the same day. Call 040-44885000.
International enquiries: info@kimsneurosciences.com